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Abstract
Background: Stroke survivors encounter emotional problems in the chronic phase after stroke. Post-stroke depressive
symptoms have major impact on health-related quality of life (HRQol) and lead to increased hospitalization and
therefore substantial healthcare costs. We present a cost-effectiveness and cost-utility evaluation of a cognitive
behavioural therapy augmented with occupational and movement therapy to support patients with a stroke with
depressive symptoms in goal-setting and goal attainment (augmented CBT) in comparison with a computerized
cognitive training program (CogniPlus) as a control intervention.
Methods: A trial-based economic evaluation was conducted from a societal perspective with a time horizon of
12 months. Stroke patients (aged 18+ years) with signs of depression (Hospital Anxiety and Depression Scale
(HADS) – subscale depression > 7) were eligible to participate. Primary outcomes were the HADS and Quality
Adjusted Life Years (QALYs) based on the three-level five-dimensional EuroQol (EQ-5D-3 L). Missing data were
handled through mean imputation (costs) and multiple imputation (HADS and EuroQol), and costs were
bootstrapped. Sensitivity analyses were performed to test robustness of baseline assumptions.
Results: Sixty-one patients were included. The average total societal costs were not significantly different between the
control group (€9,998.3) and the augmented CBT group (€8,063.7), with a 95 % confidence interval (−5,284, 1,796). The
augmented CBT intervention was less costly and less effective from a societal perspective on the HADS, and less costly
and slightly more effective in QALYs, in comparison with the control treatment. The cost-effectiveness and cost-utility
analyses provided greater effects and fewer costs for the augmented CBT group, and fewer effects and costs for the
HADS. Based on a willingness to pay (WTP) level of €40,000 per QALY, the augmented CBT intervention had a 76 %
chance of being cost-effective. Sensitivity analyses showed robustness of results.
Conclusion: The stroke-specific augmented CBT intervention did not show convincing cost-effectiveness results. In
addition to other literature, this study provided new insights into the potential cost-effectiveness of an adjusted
cognitive behavioural therapy intervention. However, as our study showed a 76 % chance of being cost-effective for
one outcome measure (QALY) and did not provide convincing cost-effectiveness results on the HADS we recommend
further research in a larger population.
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Background
Stroke is a leading cause of death and a source of persistent
disability around the world [1]. Annually, 6.7 million people
die from stroke, representing 12 % of all global deaths [2].
As a disease of aging, the prevalence of stroke is expected
to increase significantly around the world in the years
ahead as the global population older than 65 years of
age continues to increase by approximately nine million
people per year [3]. Stroke survivors often encounter
severe cognitive and emotional consequences [4]. Post-
stroke depressive symptoms occur frequently in the
chronic phase after stroke [5–9]. Recent data from the
National Stroke Association (United Kingdom) show
that approximately one-third of stroke survivors is affected
by varying degrees of post-stroke depression amongst
other symptoms [10]. In addition, these symptoms often
coincide with increased feelings of anxiety [11]. Besides
the major impact on health-related quality of life (HRQol)
[12], post-stroke depressive symptoms are associated with
increased hospitalization and therefore substantial health-
care costs [13].
Stroke puts a high burden of disease on patients and
their caregivers, as well as a considerable financial burden
on society. Currently, approximately 3–4 % of total health-
care expenditures in Western countries are spent on stroke
[14]. Even greater healthcare expenditures are likely in the
near future, with expected increases in the elderly popula-
tion and the availability of new and better treatments for
stroke patients. As healthcare resources are limited and
choices have to be made, interest in the economic aspect of
stroke and cost-effective stroke-specific interventions has
increased in the past few years [15].
Previous research has been used to evaluate different
interventions focusing on the treatment of post-stroke
depressive symptoms, such as pharmacological inter-
ventions [16, 17], yet evidence for the effectiveness of
stroke-specific psychological interventions is limited [18].
This is mainly related due to possible lack of efficacy of
the interventions under investigation, but also caused by
poor study design [19]. There are, however, indications
that the use of cognitive behavioural therapy (CBT) might
be both effective and cost-effective, based on the treat-
ment of other chronic conditions [20–25]. Psychological
interventions, such as CBT, seem promising in terms of
effectiveness because they result in fewer side effects
than medication and have a stronger effect on preventing
relapse of symptoms than pharmacotherapy [20, 26–29].
With respect to psychological interventions, fewer side ef-
fects and reduction in relapse are potentially strong indica-
tors for cost-effectiveness. Furthermore, the characteristics
of CBT seem to suggest it ought to be an especially good fit
to meet the needs of people who suffer from post-stroke
depression [17]. Depressed stroke survivors endorse signifi-
cantly more negative conditions than non-depressed stroke
survivors [30, 31] In addition, there is good evidence that
remaining active, expressing emotion and finding positive
meaning ensures good psychological adjustment in other
chronic illnesses [32].
The current study describes the cost-effectiveness and
cost-utility of a cognitive behavioural therapy augmented
with occupational and movement therapy to support stroke
patients with depressive symptoms in goal setting and goal
attainment (augmented CBT) for stroke patients suffering
from post-stroke depressive symptoms, in comparison with
a computerized cognitive training program (CogniPlus)
as a control intervention. Our aim was to determine the
cost-effectiveness of both interventions from a societal
perspective.
Methods
Guidelines
The current study and economic evaluation were per-
formed according to the Consolidated Health Economic
Evaluation Reporting Guidelines (CHEERS) [33]. The
study design and methods were approved by the medical
ethical committee of Nijmegen (The Netherlands) and
by the executive boards of all participating rehabilitation
institutions. The indented time points of assessment were
post hoc approved by the same medical ethical committee.
Design
The current study describes an economic evaluation which
was linked to the Restore4stroke CBT study: a multi-centre
randomized controlled trial (RCT) conducted in five re-
habilitation centres and in the rehabilitation department of
one general hospital in the Netherlands. The Medical Ethics
Committee of the Radboud University Medical Centre and
the executive boards of the participating institutes approved
the study. The inclusion of participants took place between
February 2012 and October 2013. All patients provided
written informed consent. The RCT was registered in the
Dutch Trial Register as NTR2999. Detailed information on
the methods of this RCT and the current study can be
found elsewhere [15, 34].
Eligibility criteria
Patients where included if they: (1) suffered any type of
stroke in the last 3 months and complaints in mood
(indicating possible symptoms of anxiety or depression)
occurred post stroke, (2) were 18 years or older, (3)
scored >7 on the HADS depression subscale (HADS-D)
[35], (4) mastered the Dutch language, and (5) had suf-
ficient communication skills based on the Mini-Mental
State Examinate [36] > 27 and had normal score (>0) on
communication items of the National Institutes of Health
Stroke Scale items [37]. Patients were excluded if they: (1)
scored < 19/20 on the Barthel Index [5] indicating premor-
bid disabilities, (2) were staying in an in-patient setting,
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(3) suffered from co-morbidity that might affect outcomes
(e.g. cancer or major psychiatric illnesses for which psy-
chological treatment was being given at the moment of
inclusion), (4) were diagnosed with a major depression
requiring medication, or (5) were diagnosed with a pre-
morbid depression or had received psychiatric care for
depression.
Interventions
The augmented CBT intervention was individually ad-
ministered and tailored according to specific subjects-
own activity-related goals. These goals could capture
domains as e.g. self-care, leisure, household, work, and
improvement of mobility-related goals such as movement
and walking. The CBT treatment program consisted of
10–12 sessions with a certified healthcare psychologist, ex-
perienced in the treatment of depression and stroke re-
habilitation. The augmentation part of the intervention
was specifically aimed at supporting patients in goal
setting and goal attainment. This part consisted of three
sessions of occupational therapy (OT) or movement
therapy (MT) provided by an occupational or movement
therapist. Each of these sessions was comprised of 20–25
min blocks divided by a 10–15 min break. If a patient’s
score on the HADS subscale anxiety (HADS-A) was > 7,
the protocol was expanded with an additional (fourth)
OT/MT session [38]. All treatments were provided at the
closest participating centre and the complete program was
executed within 4 months.
The control group was provided with an individual,
patient-tailored computerized cognitive training program
(CogniPlus) [39]. In specific self-determined cognitive
domains (e.g. attention, memory, executive functioning,
and visual attention) patients executed computer tasks on
their own performance level. This impairment-oriented
intervention consisted of 13–16 sessions provided at par-
ticipating centres under the supervision of a research as-
sistant or psychological assistant, for a period of 4 months.
We chose to compare the augmented CBT intervention to
an ‘active’ intervention (and not usual care) to control for
Hawthorne effects. Evidence from Spikman et al. [40]
showed that a similar control group did not improve in
executive functioning, and that generalisation of what was
assessed in the control intervention to daily life did not
occur. Further information on the justification of both
interventions can be found elsewhere [15, 34].
Procedure
Treating physicians and healthcare psychologists of the
participating institutes were informed about the inclusion
and exclusion criteria of the study. Accordingly, they re-
cruited eligible patients at participating centres. Potential
participants were contacted by the primary researcher (JK)
and informed about the intervention. In case of a positive
reply, an individual appointment was made to confirm the
inclusion and exclusion criteria, to obtain written consent,
and to conduct the baseline assessment. Patients were
randomly allocated to either the augmented CBT group
or control group. Stratified block randomization (block
size four) was conducted, in which level of anxiety was
a minimization factor (HADS-A > 7 vs ≤ 7). Follow-up
assessments took place at the nearest participating
centre for each patient and were conducted by a research
assistant who was blinded to the type of intervention pro-
vided to the patient. Prior to each assessment, the assessor
explicitly asked patients not to talk about the content of
their intervention. The success of assessor blinding was
ensured with a short self-constructed questionnaire at the
end of each assessment.
Time horizon
Patients were randomly allocated to one of the interven-
tions after the baseline assessment (T0). Assessments took
place post treatment (T1), at 8 months follow-up (T2) and
at 12 months follow-up (T3).
Sample size
Based on a minimal detectable effect size of 0.6 the stand-
ard deviation (SD) on the HADS (α = 0.05; β = 0.80), a
minimum of 45 participants per group was required. With
an expected dropout of 15 %, 106 participants needed to
be recruited. However, due to recruitment difficulties we
were not able to include the minimum amount of partici-
pants necessary. Reconsidering the proposed analysis of
the Restore4stroke CBT study, it was decided to add the
T1 measurement next to T2 to estimate the effect of treat-
ment outcomes. These repeated measures at T1 and T2
would reduce variance, double the power and reduce
the required sample size. Therefore, a new power (n = 53;
α = 0.05; β = 0.80) allowed us to continue with fewer par-
ticipants than originally planned. The Medical Ethics
Committee approved an amendment containing these
changes.
Outcome measures
The main outcome for the cost-effectiveness analysis
(CEA) was depression and anxiety, assessed by the HADS
(total score). The HADS is a 14-item questionnaire (seven
questions concerning ‘depression’ and seven questions
concerning ‘anxiety’) on a 4-point scale. Higher scores on
the HADS indicate greater levels of depression and/or
anxiety. The validity and reliability of the HADS has been
determined in previous research [41].
The main outcome for the cost-utility analysis (CUA)
was health-related quality of life (further referred to as
QoL), as measured by with the five-dimensional three-level
EuroQol (EQ-5D-3 L) [42]. The five EuroQol dimensions
are mobility, self-care, usual activities, pain/discomfort and
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anxiety/depression. To estimate the utility of health states
described by patients, we used the Dutch tariff [43]. Quality
adjusted life years (QALYs) were calculated by means of the
area under the curve method. Higher QALYs indicate more
improvement in QoL.
Resource use and costs
A 19-item self-report cost-questionnaire was constructed
to collect cost data from a societal perspective, based
on the steps described by Thorn [44]. The validity and
feasibility of generic self-report questionnaires has been
investigated elsewhere [45]. As a societal perspective is
a broad perspective in which all relevant costs for the
whole population are incorporated [46], we included
four main cost categories in this study: intervention,
healthcare, patient- and family-related, and productivity
costs. A bottom-up approach was used to determine
intervention costs (e.g. intervention materials, consult-
ation hours with a psychologist). Healthcare costs covered
care provider utilization (e.g. general practitioner and
medical specialist consultations), complementary medi-
cine, home care and medication. As a guideline for cal-
culating healthcare costs we used the Dutch Manual
for Costing [47].
Medical and personal aids were based on costs per
user within the aid category provided by the Dutch care
institute [http://www.gipdatabank.nl] and the costs of
prescription medicines were valued by the price per dosage
for drug costs in the Netherlands [48, 49]. Travel costs and
costs of informal care were included as patient- and family
costs. Travel costs were calculated by multiplying the aver-
age distance with standard price weights provided by The
Dutch Manual for Costing [47], corrected for the costs of
public transport and parking costs. Shadow prices were
used to determine the costs of informal care, which were
equal to the hourly wage rates of professional caregivers
(i.e. housekeepers). Productivity costs were valued accord-
ing to the human capital approach. This approach states
that productivity costs are calculated by multiplying the
number of sick days by the costs of labour, corrected for
different age categories. The human capital approach is the
international standard in calculating productivity costs,
whereas its counterpart, the friction cost method, is subject
to variability in the national economic cycles [50, 51]. Fur-
thermore, due to changes in Dutch legislations, it is unlikely
for employees that they are being replaced, making it
imperative to include long-term absenteeism as well.
Currency, price date and conversion
All costs reported in this study were expressed in Euro’s
(€). Consumer price indices were used to adjust all costs
to the index year 2012 [52]. Discounting was not neces-
sary since the follow-up period of the current study did
not exceed 1 year.
Analytic methods
Intention-to-treat was used to analyse data. Missing values
for resource use were handled by individual mean imput-
ation, the recommended imputation methods on dealing
with intermittent data in economic evaluation studies
[53]. Missing data on the main outcomes were handled by
multiple imputation (MI). MI is a technique often used to
analyse data sets with missing values; it is the process of
replacing each missing data point with a set of plausible
values to generate complete data sets [54]. Since baseline
utility measurements are included when calculating QALYs
we consider any baseline difference in utility scores as a
potential bias, regardless of whether or not this difference
is significant or not. Therefore, we used a regression based
correction method to correct for baseline differences in
utility scores [55].
An incremental cost-effectiveness ratio (ICER) was calcu-
lated by dividing the incremental costs by the incremental
effects, and an incremental cost-utility ratio was calculated
by dividing the incremental costs by the differences in
QALY. We used non-parametric bootstrapping (5000 repli-
cations) to estimate the uncertainty surrounding the ICER,
due to the highly skewed cost distribution. Bootstrapped
cost-effectiveness and cost-utility pairs were presented in
cost-effectiveness planes (CE-planes). Statistically significant
differences in costs were determined by means of a 95 %
confidence interval (further referred to as CI). If the CI
entailed a ‘0’ value, no statistical differences in costs were
found.
Furthermore, a cost-effectiveness acceptability curve
(CEAC) was made to express the probability of the
augmented CBT intervention being a cost-effective al-
ternative in comparison with the control intervention.
A CEAC shows the probability of an intervention to
be a cost-effective alternative for a certain threshold;
the amount of money society is willing to pay (WTP)
to gain one unit of effect (e.g. a one-point improve-
ment on the HADS or one QALY). For the HADS, the
WTP threshold is an unknown quantity. A previous
study on manual psychological therapy for dementia
patients used a WTP level of €500 per one-point im-
provement on the HADS [56]. The minimal important
difference of the HADS has not been established, but
in patients with chronic obstructive pulmonary disease
(COPD) a minimal important difference of 1.6 was
found [57]. The WTP threshold for a QALY differs per
country or even within countries. In the Netherlands,
the Dutch Council of Public Health and Care pub-
lished a report in 2006 regarding the burden of disease
in the Netherlands, estimating a QALY threshold for
stroke at €40,000 Euros [58]. All statistical analyses
were performed using the Statistical Package for the
Social Sciences (SPSS) version 21 or Microsoft Excel
(bootstrapping).
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Sensitivity analyses
To test the robustness of assumption made in the base
case analyses, we conducted four one-way sensitivity
analyses. First, the price for a rehabilitation day treatment
was decreased to €117, equal to a regular rehabilitation
consultation. Second, the friction cost method was used to
calculate productivity costs instead of the human capital
approach [47]. Third, we compared our base case societal
perspective for calculating costs with a healthcare perspec-
tive. Finally, as different sets of tariffs exist to calculate
utilities, we analysed the impact of the use of Dutch tariffs
versus United Kingdom (UK) tariffs [59].
Results
Sample
One hundred sixty-three patients were assessed regarding
their eligibility for participation in this study (Fig. 1).
Eighty-three patients were found ineligible based on their
HADS-D score (≤7) and 15 patients did not meet other
inclusion criteria. After baseline measurement, four pa-
tients dropped out due to various reasons. Thus, a total of
61 patients were included in this study (Table 1). Thirty-
one patients (52 %) were allocated to the augmented CBT
group and 30 patients (48 %) to the control group. As
presented in Fig. 1, the percentage of missing data at
T1 was 15 % (n = 9), at T2 was 21 % (n = 13) and at T3
was 28 % (n = 17).
Cost analysis
The average total societal costs were greater for the con-
trol group (€9,998) in comparison with the augmented
CBT group (€8,064), but this difference between the two
groups was not significant (CI: −5284, 1,796). Healthcare
costs were also greater for the control group (€5,055
compared to €3,771), but this difference was not signifi-
cant either (CI: −3,039, 465). Specialist visits was the
only cost category within healthcare costs that showed
significantly greater costs for the control group (€993)
in comparison with the augmented CBT group (€539)
(CI: −868, −38). The non-healthcare costs were also in
favour of the intervention group (€4,926 in comparison
with €4,333 in the control group), however, no significant
difference was found (CI: −2,778, 1,551). Both the prod-
uctivity costs (CI: −3,065, −93) and the productivity costs
of the caregiver (CI: −1,354, −27) were significantly greater
for the control group. As expected, intervention costs
were greater for the augmented CBT group (€1,130 in
comparison with €592). Further details are presented in
Table 2.
Cost-effectiveness and cost-utility
The CEA for the HADS showed that the augmented
CBT group induced fewer costs (−€1,913) but also fewer
effects (−0.8), resulting in an ICER of €2,395 (Table 3).
The majority of bootstrapped ICERs (58 %) were located
in the southwest (SW) quadrant of the CE-plane (Fig. 2)
Fig. 1 Inclusion of patients
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indicating fewer costs and fewer effects for the aug-
mented CBT intervention, and 29 % of the bootstrapped
ICERs were located in the dominant southeast (SE)
quadrant indicating greater effects and fewer costs for
the augmented CBT intervention.
Patients in the augmented CBT group gained slightly
more QALYs (mean: 0.01) compared to control group
patients. More QALYs gained combined with fewer soci-
etal costs (−€1,913) induced by the augmented CBT
group resulted in a dominant ICER. As presented in
Fig. 3, 31 % of the bootstrapped ICERs were located in
the SW quadrant (fewer costs and effects) of the CE-
plane and 55 % of the bootstrapped ICERs were located
in the dominant SE quadrant (fewer costs and greater
effects).
The cost-effectiveness acceptability curves (CEACs) of
the HADS and QALY are also presented in Figs. 2 and 3.
The slope of the HADS CEAC indicates that with a WTP
threshold of €2,500, the probability of the augmented CBT
intervention being cost-effective was 49 %. Furthermore,
greater WTP levels showed an increasing decline in the
probability of the augmented CBT intervention being
cost-effective. In the Netherlands, there is no fixed WTP
threshold for a QALY, but the threshold is dependent on
the burden of disease [58]. Based on the burden of stroke,
a WTP level of €40,000 was considered acceptable [58].
Using this threshold, the QALY CEAC indicates that there
is a 76 % chance that the augmented CBT intervention
will be cost-effective.
Sensitivity analysis
A sensitivity analysis was performed to estimate the impact
of reducing the price of a rehabilitation treatment day, on
the cost-effectiveness results (Table 4). The analysis proved
robustness of the base case assumption for this parameter
for both the HADS and QALY, as it resulted in a slightly
lower ICER and no major changes in distributions on the
CE-plane (7. 4). Calculating productivity costs by means of
the friction cost method resulted in a much lower ICER for
both the HADS and QALY and major shifts in distributions
on the CE-plane to both ‘west’ quadrants (indicating fewer
costs for the augmented CBT group). Estimating total costs
from a healthcare perspective resulted in lower ICERs for
both outcome measures; this was due to fewer cost categor-
ies being included. A major shift on the CE-plane of the
QALY is noticeable towards the northeast (NE) quadrant
(greater costs and greater effects). Finally, UK tariffs
were used to calculate QALYs resulting in a decrease in
ICER, and again, a shift on the CE-plane towards the
SE quadrant.
Conclusions
To our knowledge, this is the first cost-effectiveness ana-
lysis performed on a prospective randomized comparison
Table 1 Baseline patients’ characteristics (n = 61)
Augmented CBT (n = 31) CogniPlus (n = 30)
Demographic characteristics n. n.
Mean age in years (SD1) 31 62.2 (8.3) 30 60.0 (10.5)
Gender (% men) 31 61.3 30 63.3
Paid work (%) 31 29 30 43.3
Hours worked/week (SD) 31 2.3 (5.6) 30 5.5 (12.8)
Stroke characteristics
Time since stroke in months (SD) 31 43.9 (51.1) 30 40.2 (41.9)
Type of stroke (% infarction) 28 75 28 85.7
Affected hemisphere (% right) 28 30.8 26 39.3
Outcome measures
Effects
HADS Total (SD) 31 22.3 (6.2) 30 22.3 (6.7)
HADS Anxiety (SD) 31 9.9 (4.1) 30 10.0 (4.4)
HADS Depression (SD) 31 12.5 (3.3) 30 12.33 (3.4)
Utility (SD) 31 0.58 (0.27) 30 0.47 (0.30)
Costs
Healthcare costs, € (SD) 31 2,213.4 (880.9) 30 2,051.8 (501.6)
Non-healthcare costs, € (SD) 31 2,528.3 (712.4) 30 1,962.3 (518.1)
Total societal costs, € (SD) 31 4,717.7 (1,203.9) 30 4,038.4 (853.7)
1SD: standard deviation
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of an augmented CBT intervention versus computerized
cognitive training (CogniPlus) for post-stroke depressive
symptoms.
The results of this study provides evidence that, using
the HADS as an outcome, the augmented CBT inter-
vention for stroke patients was less costly and less ef-
fective from a societal perspective and less costly and
slightly more effective in terms of QALYs, compared to
the control treatment. Cost differences between the
two groups could be explained by costs of admission to
a hospital, specialist consultations and home adjust-
ments, but the larger part of the difference in total
costs was due to productivity costs of both the patient
and the caregiver which were both significantly less in
the augmented CBT group. The fact that, at baseline,
43.3 % of the control group had paid work, in compari-
son with only 29 % of the augmented CBT group, and
that patients in the control group worked more than
twice the number of hours per week might explain this
difference.
Table 2 Average resource use and costs per category over 12 months (bootstrapped)
Augmented CBT intervention (n = 31) CogniPlus intervention (n = 30)
Category Unit price Average use
(SD)
Average costs, Euros
(SD)
Average use
(SD)
Average costs, Euros
(SD)
95 % CI1
Healthcare
Hospital Night 0.5 (2.3) 255.9 (187.7) 1.6 (4.2) 787.8 (370.9) (−1,428, 173)
Rehabilitation centre Night 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) (0,0)
Nursing home Night 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) (0,0)
General practitioner Consultation 9.6 (9.2) 285.8 (48.2) 10.8 (10.6) 328.2 (55.6) (−186, 93)
Specialist Consultation 4.2 (5.1) 538.8 (113.1) 7.8 (7.9) 993.1 (172.2) (−868, −38)2
Physiotherapy Consultation 23.5 (34.0) 893.2 (233.3) 26.5 (31.7) 1,006.1 (209.8) (−702, 525)
Remedial therapy Consultation 5.5 (11.6) 207.0 (79.8) 4.8 (9.6) 177.3 (62.6) (−166, 234)
Mensendieck Consultation 0.5 (2.9) 20.4 (19.1) 0.0 (0.0) 0.0 (0.0) (0, 58)
Occupational therapy Consultation 2.8 (5.4) 64.1 (22.1) 0.9 (2.9) 20.4 (12.3) (−2, 98)
Activity therapy Consultation 1.3 (5.4) 46.1 (35.2) 4.2 (13.6) 155.4 (92.6) (−330, 57)
Speech therapy Consultation 2.6 (10.9) 88.5 (65.7) 1.4 (5.6) 50.2 (35.7) (−88, 209)
Social work Consultation 0.2 (0.8) 12.9 (9.7) 1.0 (3.3) 66.4 (39.9) (−140, 9)
Psychologist Consultation 7.0 (8.6) 581.6 (126.4) 5.9 (7.7) 487.7 (115.7) (−231, 430)
Psychiatric nurse Consultation 0.0 (0.0) 0.0 (0.0) 0.2 (0.9) 6.4 (5.0) (−18, 0)
Psychiatrist Consultation 0.0 (0.0) 0.0 (0.0) 0.2 (0.9) 17.8 (18.0) (−55, 0)
Rehabilitation day
treatment
Day 1.4 (5.5) 375.9 (264.2) 2.3 (6.9) 591.2 (317.2) (−1,034, 542)
Medication Other 410.0 (114.2) 374.3 (108.5) (−234, 208)
Subtotal 3,771.3 (551.5) 5,055.3 (713.0) (−3,039, 465)
Non-healthcare
Travel costs Other 289.4 (48.9) 301.3 (41.2) (−137, 119)
Productivity costs Hours/week 0.3 (1.2) 243.5 (206.4) 1.7 (4.3) 1,648.8 (728.5) (−3,065, −93)2
Productivity costs
caregiver
Hours/week 0.0 (0.1) 12.9 (12.4) 0.6 (2.1) 615.2 (347.8) (−1,354, −27)2
Paid help Hours 45.9 (71.2) 1,728.8 (477.2) 28.2 (53.3) 1,061.2 (368.9) (−465, 1,790)
Unpaid help Hours 60.4 (141.9) 813.7 (315.7) 40.3 (86.7) 539.9 (204.7) (−483, 261)
Tools3 Item 157.0 (54.0) 78.6 (33.5) (−46, 209)
Home adjustments3 Item 0.0 (0.0) 134.5 (120.2) (−400, 0)
Subtotal 4,333.6 (745.7) 4,926.0 (835.3) (−2,778, 1,551)
Intervention costs Other 1,129.8 592.1
Total societal costs 8,063.7 (1,126.1) 9,998.3 (1,370.1) (−5,284, 1,796)
1significant difference
295 % Confidence Interval level
3Tools: e.g. brace, special glasses; Home adjustments: e.g. toilet or shower adjustment
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The results of the cost-effectiveness analysis showed
that the probability of the augmented CBT intervention
being cost effective was 49 % for a WTP of €2,500. No
fixed WTP threshold for the HADS exists, but previous
research used a WTP of €500 per point improvement on
the HADS based on expert opinion [56]. A dominant
ICER for the QALY was found, indicating greater effects
and fewer costs for the augmented CBT group. Com-
bined with a high probability of the augmented CBT
intervention being cost-effective, the results from the
cost-utility analysis were in favour of the augmented
CBT intervention. However, due to the minimal difference
in effects (mean: 0.1), these results should be interpreted
with caution.
In general, the sensitivity analyses showed robustness
of results. For the HADS, a distinct shift in the distribution
of bootstrapped ICERs was noticeable when calculating
productivity costs with the friction method. This might be
expected, since the friction cost method accounts for a
shorter period of productivity losses resulting in fewer
costs, and a lower ICER with the same difference in HADS
score and a slightly greater probability of the augmented
CBT intervention being cost-effective. This was also ob-
served for the friction method, employed as a sensitivity
analysis with regard to QALYs. A major shift was noticeable
when conducting the cost-utility analysis from a healthcare
perspective instead of the societal perspective. It appeared
that the augmented CBT group induced both greater costs
Fig. 2 Cost-effectiveness plane HADS and cost-effectiveness acceptability curve HADS
Table 3 Mean cost and effect differences between the Augmented CBT group and CogniPlus group, incremental cost-effectiveness
ratios and cost-effectiveness plane distributions
Sample size ΔCosts ΔEffects ICER1 Distribution cost-effectiveness plane (quadrant, %)2
Analysis Effect measure Augmented CBT CogniPlus Euro NE SE (dominant) SW NW (inferior)
Cost-effectiveness HADS 31 30 −1,912.6 −0.8 2,395.3 5 29 58 8
Cost-effectiveness QALY 31 30 −1,912.6 0.01 −160,389.9 5 55 31 9
1ICER: incremental cost-effectiveness ratio
2NE (northeast quadrant): SM more effective and more costly compared to EDU
SE (southeast quadrant): SM more effective and less costly compared to EDU
SW (southwest quadrant): SM less effective and less costly compared to EDU
NW (northwest quadrant): SM less effective and more costly compared to EDU
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Fig. 3 Cost-effectiveness plane QALY and cost-effectiveness acceptability curve QALY
Table 4 Sensitivity analysis
Analysis1 ΔCosts (€) ΔEffects ICER2 Distribution cost-effectiveness plane (quadrant, %)3
NE SE (dominant) SW NW (inferior)
Base case HADS −1,912.6 −0.8 2,395.3 5 29 58 8
Unit price day of rehabilitation −1,787.0 −0.8 2,238.0 6 29 57 8
Friction costs −796.4 −0.8 997.4 12 23 46 19
Healthcare perspective −1,281.4 −0.8 1,604.7 3 31 61 5
Base case QALY −1,912.6 0.01 −160,389.9 5 55 31 9
Unit price day of rehabilitation −1,787.0 0.01 −149,859.6 4 54 33 9
Friction costs −796.4 0.01 −66,784.4 12 46 24 18
Healthcare perspective 1,281.4 0.01 107.454.7 52 6 6 36
QALY UK tariff −1,912.6 0.04 −51.797.4 7 65 22 6
1Base case analysis values a day of rehabilitation day as a hospital treatment day (€266.53), calculates production costs by means of human capital method, uses
the societal perspective to calculate total costs
corrects for baseline differences with regression analysis and calculates utilities with a Dutch tariff. Sensitivity analyses values a rehabilitation treatment day as a
rehabilitation contact (€116.81), calculates production
costs with the friction cost method, estimates total cost from a healthcare perspective calculates utilities with a UK tariff
2ICER: incremental cost-effectiveness ratio
3NE (northeast quadrant): SM more effective and more costly compared to Edu
SE (southeast quadrant): SM more effective and less costly compared to Edu
SW (southwest quadrant): SM less effective and less costly compared to Edu
NW (northwest quadrant): SM less effective and more costly compared to Edu
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and greater effects leading to a shift on the CE plane
towards the NE quadrant. This, and the fact that the
difference in effect was minimal, indicated that the major-
ity of total costs for the control group were accounted for
by non-healthcare costs.
To our knowledge, this current study provides new
but preliminary evidence on the cost-effectiveness of a
stroke-specific augmented cognitive behavioural therapy.
Four previous studies investigating a comparable inter-
vention in different populations showed similar results
[22–24, 27]. More precisely, recent research on the ef-
fectiveness of an online CBT intervention for depressive
patients found greater costs for CBT group and a cost
per QALY gained of €23.857, which is below the acceptable
UK threshold of €27.784 per QALY [21]. Although this
study was conducted from a National Health Services
(NHS) perspective and the CBT intervention was compared
with care as usual, the conclusions drawn from this study
where in line with the current study results, indicating the
potential cost-effectiveness of CBT. Another study evaluat-
ing the effectiveness of CBT for depressive patients in a
non-stroke population reported greater costs and greater
effects in terms of QALYs, resulting in a base case ICER of
€20.714 [25]. Two other studies on the cost-effectiveness of
CBT for patients with low-back pain and for people with
schizophrenia-spectrum disorder also showed the possible
cost-effectiveness of cognitive behavioural therapy [22, 24].
It is important to note that these previous studies chose
‘care as usual’ as comparator, whereas the current study
chose a computerized training (CogniPlus). The choice of
comparator is a critical design parameter in economic
evaluation research and may influence study results [60].
Strengths and limitations
To our knowledge, there has been no previous economic
evaluation research on a stroke-specific cognitive behav-
ioural therapy. Furthermore, the cost-effectiveness and
cost-utility analyses in this study were conducted from a so-
cietal perspective, which is also considered to be a strength
because it provides extensive evidence on a broad range of
costs. Finally, both the outcome assessors and research
assistants were blinded for the randomised treatment.
The current study was also subject to several limitations.
First, due to recruitment difficulties we were not able to
include the desired amount of participants, which was the
reason for performing a new power calculation. Still, the
current study results must be interpreted with caution due
to the small sample size. Next, we had to deal with a con-
siderable number (n = 17; 28 %) of missing values on T3
measurement concerning the HADS and EQ-5D-3 L. A
multiple imputation (MI) method was used to handle
these missing values [54]. There are alternative methods
for imputation, such as linear mixed models, but since
cost-effectiveness analysis requires individual patient data
we believe that MI was the best method for the analyses
performed in the current study. Also, productivity costs of
the caregivers were estimated with a mean hourly wage
and a mean age, since information with respect to the em-
ployment of caregivers was limited. Finally, we found and
measured differences between interventions within the
time horizon chosen for this study. However, with pro-
gressing insight, we would argue that it would be interest-
ing to expand the time horizon, by adding extra follow-up
measurement moments or using modelling techniques in
further research in order to identify the long-term effects
of both interventions in comparison to each other.
Concluding remarks
Taking into account the limitations of the current study,
we conclude that the preliminary results of the cost-
effectiveness of the stroke-specific augmented CBT
intervention under investigation were not convincing. As
our study showed a 76 % chance of being cost-effective for
one outcome measure (QALY) and did not provide con-
vincing cost-effectiveness results on the HADS. However,
other studies showed the potential for the augmented
CBT intervention to be cost-effective in treating depres-
sion. Although we have argued why we have chosen an
‘active’ control intervention, it would be very interesting to
investigate the effect of including a care as usual group as
third study arm in future research. Also, in addition to
other literature, this study provided new insights into
the potential cost-effectiveness of an adjusted cognitive
behavioural therapy intervention. Therefore, for further
research we would recommend recruitment of a larger
stroke population, i.e. in multiple sites.
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